Sean Wuxiong Cao - 22 Jun 2026 Form 4 Insider Report for NovaBridge Biosciences (NBP)

Reporting relationship: Chief Bus. Development Officer, Director
Issuer ticker: NBP
Reported as of: 22 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 24 Jun 2026, 19:22:27 UTC
Prior SEC filing: 18 May 2026
Source filing: View source filing
Reporting owner signature: /s/ Xi-Yong (Sean) Fu as attorney-in-fact

Key filing fact

Sean Wuxiong Cao filed Form 4 for NovaBridge Biosciences (NBP) on 24 Jun 2026.

Key facts

This page summarizes Sean Wuxiong Cao's Form 4 filing for NovaBridge Biosciences (NBP).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 24 Jun 2026, 19:22.

Change

Previous filing in this sequence was filed on 18 May 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002109966 Primary reporting owner

Cao Sean Wuxiong

Relationship: Chief Bus. Development Officer, Director
Address: C/O NOVABRIDGE BIOSCIENCES, 2440 RESEARCH BOULEVARD, SUITE 400, ROCKVILLE
Signature: /s/ Xi-Yong (Sean) Fu as attorney-in-fact
Signature date: 24 Jun 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

NBP transaction Derivative

Restricted Share Units

Award

Transaction value
Shares: +181,280
Change %
Price: $0.000000^*
Shares after: 181,280
Date: 22 Jun 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 181,280
Exercise price
Footnotes: F1, F2, F3, F4

NBP transaction Derivative

2025 Employee Share Option (right to buy)

Award

Transaction value
Shares: +181,290
Change %
Price: $0.000000^*
Shares after: 181,290
Date: 22 Jun 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 181,290
Exercise price: $1.53
Footnotes: F2, F4, F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

Each restricted stock unit ("RSU") represents a contingent right to receive one American Depositary Shares ("ADS").

Footnote F2

Number of underlying securities and exercise price expressed in terms of ADSs.

Footnote F3

The RSUs shall vest over four years, with one-fourth vesting on September 3, 2026 and the balance vesting ratably over the subsequent 12 quarters on the third day of each third month.

Footnote F4

The Ordinary Shares may be represented by ADSs. Each 10 ADSs represent 23 Ordinary Shares of the Issuer.

Footnote F5

The option vests, if at all, in eight equal quarterly installments following the date on which the 30-trading-day weighted average price of the Issuer's ADS (based on trading days only) is at or above US$8.00.